Results 91 to 100 of about 46,021 (214)

BRCA2 3ʹ-UTR Polymorphism rs15869 Alters Susceptibility to Papillary Thyroid Carcinoma via Binding hsa-mir-1178-3p

Pharmacogenomics and Personalized Medicine, 2021
Nan Guo,1 Peng Qu,2 Hao Li,2 Liuli Liu,2 Hao Jin,3 Renqi Liu,3 Zhen Zhang,3 Xuan Zhang,2 Yingchun Li,4 Xiaobo Lu,2 Yuejiao Zhao1 1Department of Head and Neck Surgery, Cancer Hospital of China Medical University, Liaoning Cancer Hospital & Institute ...
Guo N, Qu P, Li H, Liu L, Jin H, Liu R, Zhang Z, Zhang X, Li Y, Lu X, Zhao Y   +10 more
doaj  

Molecular Alterations in Osteosarcomas of the Oral and Maxillofacial Region: A Scoping Review

Journal of Oral Pathology &Medicine, EarlyView.
ABSTRACT Background Given the rarity and aggressive nature of osteosarcomas (OS) in the oral and maxillofacial region, understanding their molecular alterations is essential to improve diagnosis, prognosis, and guide targeted therapies. This study aimed to map molecular alterations associated with oral and maxillofacial OS, providing an overview of the
Iara Vieira Ferreira, Reydson Alcides de Lima‐Souza, Moisés Willian Aparecido Gonçalves, Carlos Takahiro Chone, Arthur Antolini‐Tavares, Albina Altemani, Fernanda Viviane Mariano   +6 more
wiley   +1 more source

An Update on Early‐Onset Breast Cancer: Incidence, Risk Factors, Genetic Testing, and Treatment

Computational and Systems Oncology, Volume 6, Issue 1, December 2026.
ABSTRACT Early‐onset breast cancer presents in patients typically under the age of 40, while very early‐onset breast cancer is usually viewed as breast cancer occurring before the age of 35. Early‐onset breast cancer demonstrates specific molecular properties and has worse outcomes compared to its late‐onset breast cancer counterpart.
Leila Jahangiri
wiley   +1 more source

Challenges in the future of cancer screening

International Journal of Cancer, Volume 158, Issue 8, Page 2013-2022, 15 April 2026.
Abstract The purpose of cancer screening is to reduce mortality, and ideally incidence, from the cancer screened for. Until recently, cancer screening has been offered to all persons in pre‐defined sex‐ and age‐groups. The exception is lung screening which is targeted to high‐risk individuals.
Elsebeth Lynge, Berit Andersen, Stig E. Bojesen, Lone Kjeld Petersen, Mickael Bech, Martin Bøgsted, Mie Seest Dam, Søren Egstrand, Anne Mette Fløe Hvass, Camilla J. Kobylecki, Kristina Lång, Mads Nielsen, Giorgi Paolo Rossi, Michael Stenger, Ilse Vejborg, Future of Cancer Screening Working Group, Vibe Munk Bertelsen, Janne Bigaard, Karen Omann Binderup, Lennart Friis‐Hansen, Stine Bisgaard Greve, Jessica Xin Hjaltelin, Rikke Hedegaard Jensen, Gitte Jessing, Pia Kirkegaard, Mette Hartmann Nonboe, Tina Bech Olesen, Katrine Stolberg, Signe Bülow Therkildsen, Mette Kielsholm Thomsen   +29 more
wiley   +1 more source

Adequacy evaluation of 22‐gauge needle endoscopic ultrasound‐guided tissue acquisition samples and glass slides preparation for successful comprehensive genomic profiling testing: A single institute experience

DEN Open, Volume 6, Issue 1, April 2026.
Abstract Objectives This study aimed to evaluate the successful sequencing rate of Foundation One CDx (F1CDx) using small tissue samples obtained with a 22‐gauge needle (22G) through endoscopic ultrasound‐guided fine needle acquisition (EUS‐TA) and to propose guidelines for tissue quantity evaluation criteria and proper slide preparation in clinical ...
Tami Nagatani, Yoji Wani, Masahiro Takatani, Soichiro Fushimi, Hirofumi Inoue, Shinichiro Hori, Kyohei Kai, Hideki Yamamoto, Tetsuya Okazaki, Maki Tanioka, Hiroyuki Okada, Akira Hirasawa   +11 more
wiley   +1 more source

Results and Exploratory Biomarker Analyses of a Phase II Study CHANGEABLE: Combination of PD‐1 Inhibitor and Niraparib in GErm‐Line‐mutAted Metastatic Breast Cancer

MedComm, Volume 7, Issue 4, April 2026.
This phase II trial evaluated the efficacy and safety of niraparib combined with HX008 in metastatic breast cancer (MBC) patients with germline DNA damage response (DDR) gene mutations. This chemotherapy‐free regimen demonstrates promising efficacy and a tolerable safety profile in MBC patients with germline DDR mutations, providing a novel therapeutic
Jian Zhang, Yiqun Du, Yanchun Meng, Yizi Jin, Mingxi Lin, Xuchen Shao, Xiaojun Liu, Yuxin Mu, Yun Liu, Zhen Hu   +9 more
wiley   +1 more source

Expanding Access to Genome Sequencing: Higher Diagnostic Yield in Self‐Referred Participants From the CincyKidsSeq Study and Implications for Hybrid Models of Genetic Service Delivery

Clinical Genetics, Volume 109, Issue 4, Page 717-724, April 2026.
Genome sequencing helped find answers for 1 in 5 children with rare conditions in an outpatient study looking at hybrid genetic care delivery. Families who chose testing themselves had the highest diagnostic yield, showing that self‐referral may be a helpful way to improve access to genetic care.
Kristin Theobald, Amelle Shillington, Farrah Jackson, Jaime Lopes, Casey J. Brewer, Brian Dawson, Gang Wu, James Denton, Mike Pauciulo, Xue Zhang, Anne Slavotinek   +10 more
wiley   +1 more source

Association Between Germline BRCA1/2 Gene Variants and Clinicopathological Features of Ovarian Cancer

International Journal of General Medicine
Yu Luo,1,2 Ru Pan,1,2 Hui Rao,2,3 Xing Chen,4 Haikun Yang1,2 1Department of Gynaecology, Meizhou People’s Hospital, Meizhou Academy of Medical Sciences, Meizhou, People’s Republic of China; 2Meizhou Municipal Engineering and Technology Research Center ...
Luo Y, Pan R, Rao H, Chen X, Yang H
doaj  

Long‐term impact of stressful life events on breast cancer risk: A 36‐year genetically informed prospective study in the Finnish Twin Cohort

International Journal of Cancer, Volume 158, Issue 6, Page 1489-1497, 15 March 2026.
What's new? Breast cancer results from a combination of genetic and environmental causes, and the cumulative effect of stressful life events may be a contributing factor. Here, the authors analyzed data from cohort and twin‐pair studies including 36 years of follow‐up to find out how stressful life events affect breast cancer risk. They found that even
Elissar Azzi, Hannes Bode, Teemu Palviainen, Mikaela Hukkanen, Miina Ollikainen, Jaakko Kaprio   +5 more
wiley   +1 more source

Olaparib for patients with tumors harboring alterations in homologous recombination repair genes: Results from the drug rediscovery protocol

International Journal of Cancer, Volume 158, Issue 6, Page 1617-1627, 15 March 2026.
What's new? PARP inhibitors are effective in patients with inactivating alterations in the BRCA1/2 genes across tumor types. However, the efficacy of PARP inhibitors in patients with other inactivated homologous recombination repair genes remains unclear. This knowledge gap and discrepancies in EMA/FDA approvals highlight the need for better biomarkers.
Ilse A. C. Spiekman, Niven Mehra, Laurien J. Zeverijn, Birgit S. Geurts, Karlijn Verkerk, Soemeya F. Haj Mohammad, Vincent van der Noort, Paul Roepman, Wendy W. J. de Leng, Anne M. L. Jansen, Addy C. M. van de Luijtgaarden, Theo van Voorthuizen, Tineke E. Buffart, Hans Gelderblom, Emile E. Voest, Henk M. W. Verheul   +15 more
wiley   +1 more source